The Global Pediatric Vaccines Market to 2024: Increase in the Government & Non-government Funding in R&D - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 23, 2019--
The “Pediatric Vaccines Market - Growth, Trends, and Forecast (2019 - 2024)” report has been added to ResearchAndMarkets.com’s offering.
The global pediatric vaccine market is expected to register 11.7% CAGR during the forecast period 2019-2024.
The growth of the pediatric vaccines market is attributed due to the rising burden of chronic disease with the importance and awareness of immunization, technological advancements in vaccines, an increase in the government and non-government funding in R&D.
As immunization plays a significant role in modern medicine, there are several international programs for children, which may vary based on the disease. However, these programs are primarily driving the demand for the pediatric vaccines market.
There are several chronic diseases among children, which make them further susceptible to severe manifestations and complications with chronic diseases, For example, diseases, such as allergic, cardiorespiratory, hematologic, metabolic, and renal disorders, among others, lead to an increased risk of developing influenza, varicella, and pneumococcal infection. The parental understanding regarding these complications and immunization benefits is also required to raise awareness regarding pediatric vaccines.
The television, by far, is the most common source of information, followed by health professionals, newspapers, and magazines. The uptake of pediatric vaccination has improved through community-based vaccination program, which communicates the benefits and effectiveness of vaccines, hence promoting the growth of the pediatric vaccines market.
Furthermore, government initiatives, like Vaccines for Children Program, provides vaccines to children who lack health insurance or cannot afford the cost of vaccination, which is funded by the Centers for Medicare and Medicaid Services (CMS) to the Centers for Disease Control (CDC), and approved by the Office of Management and Budget.
The Conjugate Vaccine Segment, under Technology, is Expected to Grow at the Fastest Rate
The conjugate vaccine segment held a maximum share in 2018, and is likely to witness a rapid growth during the forecast period, due to the increasing prevalence of pneumococcal and meningococcal infections, and rise in the awareness regarding the prevention of infection, by government initiatives.
The North American Region Holds the Largest Market Share
North America is expected to be the primary region for the pediatric vaccines market, over the forecast period. The scheduled children immunization programs under the Centers for Disease Control and Prevention (CDC), high funding, wide commercial availability of vaccines, and the awareness in society regarding vaccines contribute to the sustained growth in the United States.
In Canada, the vaccination schedule for infants and children are regularly updated by the Government of Canada, in collaboration with the Canadian Nursing Coalition for Immunization (CNCI) and the Canadian Immunization Committee (CIC). The well-structured healthcare services boost the growth of the pediatric vaccines market in North America.
The pediatric vaccines market consists of several major players, including GlaxoSmithKline PLC, Merck & Co. Inc., Novartis AG, etc. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, and partnerships, which help them in strengthening their market position.
Key Topics Covered
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Chronic Diseases with the Importance & Awareness of Immunization
4.2.2 Technological Advancements in Vaccines
4.2.3 Increase in the Government & Non-government Funding in R&D
4.3 Market Restraints
4.3.1 Cost of Immunization
4.3.2 Low Medical Coverage and Healthcare Services in Low- and Middle-income Countries
4.4 Porter’s Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Vaccine Type
5.2 By Technology
5.2.1 Live Attenuated
5.2.5 Other Technologies
5.3 By Application
5.3.1 Infectious Disease
5.3.4 Other Applications
5.4.1 North America
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.4.4 Middle East & Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East & Africa
5.4.5 South America
188.8.131.52 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GlaxoSmithKline PLC
6.1.2 Indian Immunologicals Limited
6.1.4 Merck & Co. Inc.
6.1.5 Mitsubishi Tanabe Pharma Corporation
6.1.6 Novartis AG
6.1.7 Pfizer Inc.
6.1.8 Sanofi S.A.
6.1.9 Seqirus (CSL Limited)
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/1q2ipv
View source version on businesswire.com:https://www.businesswire.com/news/home/20190523005659/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/23/2019 01:08 PM/DISC: 05/23/2019 01:08 PM